AU2001253124A1 - Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties - Google Patents

Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties

Info

Publication number
AU2001253124A1
AU2001253124A1 AU2001253124A AU5312401A AU2001253124A1 AU 2001253124 A1 AU2001253124 A1 AU 2001253124A1 AU 2001253124 A AU2001253124 A AU 2001253124A AU 5312401 A AU5312401 A AU 5312401A AU 2001253124 A1 AU2001253124 A1 AU 2001253124A1
Authority
AU
Australia
Prior art keywords
alkyl
compound
aryl
mmol
conhch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253124A
Other languages
English (en)
Inventor
Ashok Arasappan
Kevin X. Chen
Ashit Ganguly
Viyyoor M. Girijavallabhan
Haining Gu
Edwin Jao
Vincent S. Madison
F. George Njoroge
Tejal N. Parekh
Andrew J. Prongay
Anil Saksena
Srikanth Venkatraman
Bancha Vibulbhan
Nanhua H. Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU2001253124A1 publication Critical patent/AU2001253124A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001253124A 2000-04-05 2001-04-03 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties Abandoned AU2001253124A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19460700P 2000-04-05 2000-04-05
US60194607 2000-04-05
PCT/US2001/010869 WO2001077113A2 (en) 2000-04-05 2001-04-03 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties

Publications (1)

Publication Number Publication Date
AU2001253124A1 true AU2001253124A1 (en) 2001-10-23

Family

ID=22718227

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253124A Abandoned AU2001253124A1 (en) 2000-04-05 2001-04-03 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties

Country Status (26)

Country Link
US (1) US6846802B2 (enExample)
EP (1) EP1268525B1 (enExample)
JP (1) JP4748911B2 (enExample)
KR (1) KR20030036152A (enExample)
CN (1) CN1441806A (enExample)
AR (1) AR029903A1 (enExample)
AT (1) ATE419270T1 (enExample)
AU (1) AU2001253124A1 (enExample)
BR (1) BR0109861A (enExample)
CA (1) CA2405521C (enExample)
CZ (1) CZ20023321A3 (enExample)
DE (1) DE60137207D1 (enExample)
EC (1) ECSP014009A (enExample)
ES (1) ES2317900T3 (enExample)
HK (1) HK1047947A1 (enExample)
HU (1) HUP0400456A3 (enExample)
IL (1) IL151934A0 (enExample)
MX (1) MXPA02009920A (enExample)
NO (1) NO20024797L (enExample)
NZ (1) NZ521455A (enExample)
PE (1) PE20020188A1 (enExample)
PL (1) PL359359A1 (enExample)
RU (1) RU2002129564A (enExample)
SK (1) SK14192002A3 (enExample)
WO (1) WO2001077113A2 (enExample)
ZA (1) ZA200207845B (enExample)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA79749C2 (en) 1996-10-18 2007-07-25 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
EP1481967B1 (en) 2002-03-05 2011-05-04 Sumitomo Chemical Company, Limited Process for the preparation of biaryl compounds
CA2481369C (en) 2002-04-11 2012-07-10 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
DE602004010137T2 (de) 2003-05-21 2008-09-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbindungen als hepatitis c inhibitoren
CA2528375C (en) 2003-06-18 2013-11-19 Tranzyme Pharma, Inc. Macrocyclic antagonists of the motilin receptor
EP1664090A2 (en) 2003-08-26 2006-06-07 Schering Corporation Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
TWI359147B (en) 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
AU2004274051A1 (en) 2003-09-22 2005-03-31 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
ATE497505T1 (de) 2003-09-26 2011-02-15 Schering Corp Makrocyclische inhibitoren der ns3-serinprotease des hepatitis-c-virus
MXPA06004006A (es) 2003-10-10 2006-06-28 Vertex Pharma Inhibidores de serina proteasas, especialmente de ns3-ns4a proteasa del virus de la hepatitis c.
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
WO2005051980A1 (en) 2003-11-20 2005-06-09 Schering Corporation Depeptidized inhibitors of hepatitis c virus ns3 protease
JP4682155B2 (ja) 2004-01-21 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスに対して活性な大環状ペプチド
SI1713823T1 (sl) * 2004-01-30 2010-04-30 Medivir Ab Inhibitorji HCV NS-3 serin proteaze
JP2008505849A (ja) 2004-02-04 2008-02-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特に、ｈｃｖ、ｎｓ３−ｎｓ４ａプロテアーゼの阻害剤
DE602005013922D1 (de) 2004-02-24 2009-05-28 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7816326B2 (en) 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
RU2006134005A (ru) 2004-02-27 2008-04-10 Шеринг Корпорейшн (US) Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
AR048413A1 (es) 2004-02-27 2006-04-26 Schering Corp Compuestos prolina 3,4- (ciclopentil) - fusionados , como inhibidores de serina proteasa ns3 del virus de la hepatitis c
CN1972956A (zh) 2004-02-27 2007-05-30 先灵公司 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的新化合物
TW200536528A (en) 2004-02-27 2005-11-16 Schering Corp Novel inhibitors of hepatitis C virus NS3 protease
PL1730110T3 (pl) 2004-02-27 2010-11-30 Merck Sharp & Dohme Siarkowe związki jako inhibitory proteazy serynowej NS3 wirusa zapalenia wątroby typu C
MXPA06013404A (es) 2004-05-20 2007-01-23 Schering Corp Prolinas sustituidas como inhibidores de serina proteasa ns3 de virus de hepatitis c.
JP2005350417A (ja) * 2004-06-11 2005-12-22 Dai Ichi Seiyaku Co Ltd 還元的エーテル化法を用いたピロリジン誘導体の製造法
CA2573346C (en) 2004-07-20 2011-09-20 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
WO2006026352A1 (en) 2004-08-27 2006-03-09 Schering Corporation Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2007001406A2 (en) * 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
AU2006242475B2 (en) * 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
ES2572980T3 (es) * 2005-06-02 2016-06-03 Merck Sharp & Dohme Corp. Combinación de inhibidores de la proteasa del VHC con un tensioactivo
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
US7470664B2 (en) 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
GEP20105124B (en) 2005-07-25 2010-11-25 Array Biopharma Inc Novel macrocyclic inhibitors of hepatitis c virus replication
JP4705984B2 (ja) * 2005-08-01 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤としての大環状ペプチド
US20070105781A1 (en) * 2005-08-02 2007-05-10 Steve Lyons Inhibitors of serine proteases
JP5203203B2 (ja) 2005-08-19 2013-06-05 バーテックス ファーマシューティカルズ インコーポレイテッド 製造工程および中間体
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
UA93990C2 (ru) 2005-10-11 2011-03-25 Интермюн, Инк. Соединения и способ ингибирования репликации вируса гепатита c
US7705138B2 (en) * 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
CA2629343A1 (en) 2005-11-11 2007-05-24 Vertex Pharmaceuticals, Inc. Hepatitis c virus variants
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
AU2007217355B2 (en) 2006-02-27 2012-06-21 Vertex Pharmaceuticals Incorporated Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
EP2194039A1 (en) 2006-03-16 2010-06-09 Vertex Pharmceuticals Incorporated Process for preparing optically enriched compounds
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
GB0609492D0 (en) * 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
BRPI0716060A2 (pt) 2006-08-17 2013-09-17 Boehringer Ingelheim Int inibidores de polimerase viral.
AU2007309544B2 (en) 2006-10-24 2012-05-31 Msd Italia S.R.L. HCV NS3 protease inhibitors
EP2079480B1 (en) * 2006-10-24 2013-06-05 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
AU2007309546A1 (en) 2006-10-24 2008-05-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. HCV NS3 protease inhibitors
AU2007318165B2 (en) 2006-10-27 2011-11-17 Msd Italia S.R.L. HCV NS3 protease inhibitors
EP2083844B1 (en) 2006-10-27 2013-11-27 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
EP2121707B1 (en) 2006-12-20 2012-12-05 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Antiviral indoles
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
RU2009127855A (ru) 2006-12-22 2011-01-27 Шеринг Корпорейшн (US) 4,5 циклоаннелированные производные индола для лечения или предотвращения вируса гепатита с (hcv) и родственных вирусных инфекций
MX2009006877A (es) 2006-12-22 2009-09-28 Schering Corp Derivados indolicos con anillo unido en las posiciones 5,6 y metodos de uso de los mismos.
CA2673254C (en) * 2006-12-22 2013-09-10 Schering Corporation 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
CA2679312A1 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
CN101903392A (zh) 2007-02-27 2010-12-01 弗特克斯药品有限公司 丝氨酸蛋白酶的抑制剂
US20090155209A1 (en) * 2007-05-03 2009-06-18 Blatt Lawrence M Novel macrocyclic inhibitors of hepatitis c virus replication
EP2494991A1 (en) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
AP2009005057A0 (en) 2007-05-10 2009-12-31 Array Biopharma Inc Novel peptide inhibitors of hepatitis c virus replication
CN101801982A (zh) 2007-07-17 2010-08-11 P.安杰莱蒂分子生物学研究所 用于治疗丙型肝炎感染的大环吲哚衍生物
US8927569B2 (en) 2007-07-19 2015-01-06 Merck Sharp & Dohme Corp. Macrocyclic compounds as antiviral agents
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
PE20090995A1 (es) * 2007-08-29 2009-08-03 Schering Corp Derivados indolicos 2,3-sustituidos como inhibidores del virus de la hepatitis c (vhc)
PE20090994A1 (es) * 2007-08-29 2009-08-03 Schering Corp Derivados de azaindol 2,3-sustituidos como agentes antivirales
CN101821252A (zh) * 2007-08-29 2010-09-01 先灵公司 取代的吲哚衍生物及其使用方法
WO2009032198A1 (en) 2007-08-30 2009-03-12 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
EP2219454A4 (en) 2007-11-14 2012-05-30 Enanta Pharm Inc HEMMER OF MACROCYCLIC TETRAZOLYL HEPATITIS C SERIN PROTEASE
WO2009064848A1 (en) * 2007-11-16 2009-05-22 Schering Corporation 3-heterocyclic substituted indole derivatives and methods of use thereof
WO2009064852A1 (en) * 2007-11-16 2009-05-22 Schering Corporation 3-aminosulfonyl substituted indole derivatives and methods of use thereof
EP2224801A4 (en) 2007-12-14 2011-09-28 Enanta Pharm Inc MACROCYCLIC INHIBITORS OF THE OXIMYL TYPE OF HEPATITIS C VIRUS SERINE PROTEASE
US8273709B2 (en) 2007-12-14 2012-09-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic HCV serine protease inhibitors
EA201000948A1 (ru) 2007-12-19 2011-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы
KR100967989B1 (ko) * 2008-01-16 2010-07-07 연세대학교 산학협력단 구조변경이 가능한 전환형 휠체어
EP2250174B1 (en) 2008-02-04 2013-08-28 IDENIX Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
AU2009217551B2 (en) 2008-02-25 2014-07-31 Msd Italia S.R.L. Therapeutic compounds
JP5490778B2 (ja) * 2008-03-20 2014-05-14 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルス阻害剤としてのフッ素化大環状化合物
KR20110005869A (ko) * 2008-04-15 2011-01-19 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규한 마크로사이클릭 억제제
EP2271345B1 (en) 2008-04-28 2015-05-20 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
CN102159579B (zh) * 2008-06-13 2015-03-25 默沙东公司 三环吲哚衍生物及其使用方法
EP2540349B1 (en) 2008-07-22 2014-02-12 Merck Sharp & Dohme Corp. Pharmaceutical compositions comprising a macrocyclic quinoxaline compound which is an hcv ns3 protease inhibitor
CA2734487A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8697694B2 (en) 2008-08-20 2014-04-15 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2326626B1 (en) 2008-08-20 2013-10-16 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP5654990B2 (ja) 2008-08-20 2015-01-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アゾ置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
MX2011007195A (es) 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
MX2011012155A (es) * 2009-05-13 2012-02-28 Enanta Pharm Inc Compuestos macrociclicos como inhibidores del virus de hepatitis c.
EP2435424B1 (en) 2009-05-29 2015-01-21 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
DK2368890T3 (da) * 2009-06-11 2013-07-22 Abbvie Bahamas Ltd Hepatitis C-virusinhibitorer
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
WO2011015241A1 (en) * 2009-08-05 2011-02-10 Polyphor Ag Conformationally constrained, fully synthetic macrocyclic compounds
CA2775697A1 (en) * 2009-09-28 2011-03-31 Intermune, Inc. Cyclic peptide inhibitors of hepatitis c virus replication
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
CA2782024A1 (en) 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
CA2784748A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
WO2011087740A1 (en) 2009-12-22 2011-07-21 Schering Corporation Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
WO2011103441A1 (en) 2010-02-18 2011-08-25 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CN102918049A (zh) 2010-03-09 2013-02-06 默沙东公司 稠合三环甲硅烷基化合物及其用于治疗病毒性疾病的方法
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US20140377223A1 (en) 2010-07-26 2014-12-25 Joseph A. Kozlowski Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
SG188618A1 (en) 2010-09-21 2013-04-30 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
JP2013540122A (ja) 2010-09-29 2013-10-31 メルク・シャープ・エンド・ドーム・コーポレイション 縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
BR112013026345A2 (pt) 2011-04-13 2019-04-24 Merck Sharp & Dohe Corp. composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
EP2755981A4 (en) 2011-09-14 2015-03-25 Merck Sharp & Dohme SILICULAR HETEROCYCLIC DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
EP3028265A4 (en) 2013-08-02 2017-06-21 Stephen Hollis Displacement sensor
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP3063140A4 (en) 2013-10-30 2017-11-08 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
JP2015155430A (ja) * 2015-04-02 2015-08-27 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ コンホメーションを固定された、合成マクロ環化合物
JP2017160247A (ja) * 2017-05-10 2017-09-14 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ コンホメーションを固定された、合成マクロ環化合物
US11267809B2 (en) 2017-09-14 2022-03-08 The Board Of Trustees Of The Leland Stanford Junior University BAF complex modulating compounds and methods of using the same
EP3820460A1 (en) 2018-07-12 2021-05-19 The Board of Trustees of the Leland Stanford Junior University Methods for reversing hiv latency using baf complex modulating compounds
CN113387842A (zh) * 2021-07-08 2021-09-14 成都泰和伟业生物科技有限公司 一种通过OTf胺化合成芳香伯胺的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE62868B1 (en) 1987-11-18 1995-03-08 Chiron Corp Hepatitis C virus
DK0381216T3 (da) 1989-02-01 1996-05-13 Asahi Glass Co Ltd Azeotrop eller azeotroplignende chlorfluorcarbonhydridblanding
PL169273B1 (pl) 1990-04-04 1996-06-28 Chiron Corp skierowanej przeciw wirusowi zapalenia watroby C PL
UA79749C2 (en) 1996-10-18 2007-07-25 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
IL134233A0 (en) * 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptide analogues
GB9812523D0 (en) * 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6576613B1 (en) * 1998-07-24 2003-06-10 Corvas International, Inc. Title inhibitors of urokinase
AR022061A1 (es) * 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides

Also Published As

Publication number Publication date
PL359359A1 (en) 2004-08-23
BR0109861A (pt) 2003-06-10
HUP0400456A2 (hu) 2004-06-28
ATE419270T1 (de) 2009-01-15
RU2002129564A (ru) 2004-05-10
SK14192002A3 (sk) 2003-03-04
HUP0400456A3 (en) 2005-09-28
KR20030036152A (ko) 2003-05-09
US20020107181A1 (en) 2002-08-08
CA2405521A1 (en) 2001-10-18
ZA200207845B (en) 2004-02-11
JP4748911B2 (ja) 2011-08-17
EP1268525A2 (en) 2003-01-02
JP2003530401A (ja) 2003-10-14
NO20024797D0 (no) 2002-10-04
HK1047947A1 (zh) 2003-03-14
PE20020188A1 (es) 2002-03-13
ECSP014009A (es) 2003-03-31
IL151934A0 (en) 2003-04-10
NZ521455A (en) 2004-06-25
MXPA02009920A (es) 2003-03-27
NO20024797L (no) 2002-12-04
CN1441806A (zh) 2003-09-10
WO2001077113A3 (en) 2002-06-20
EP1268525B1 (en) 2008-12-31
CZ20023321A3 (cs) 2003-01-15
DE60137207D1 (de) 2009-02-12
WO2001077113A2 (en) 2001-10-18
CA2405521C (en) 2010-06-29
ES2317900T3 (es) 2009-05-01
AR029903A1 (es) 2003-07-23
US6846802B2 (en) 2005-01-25

Similar Documents

Publication Publication Date Title
EP1268525B1 (en) Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
EP1664092B1 (en) Macrocyclic inhibitors of hepatitis c virus ns3 serine protease
AU2009210423B2 (en) Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
EP1385870B1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
EP1301486B1 (en) Imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus
EP1343807B1 (en) Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
US20020016294A1 (en) Macrocyclic NS-3 serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties
AU2001276988A1 (en) Peptides as NS3-serine protease inhibitors of hepatitis C virus
AU2002236591A1 (en) Diaryl peptides as NS3-serine protease inhibitors of hepatits C virus
AU2003216064A1 (en) Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
HK1058047B (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus